Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. alleging securities fraud that affected investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [2]. - It is alleged that the quality of Telix's supply chain and partners was also materially overstated [2]. - As a result, statements made by defendants regarding Telix's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. due to alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding Telix's progress in prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects of the company [3]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation does not require serving in this role [4]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly making false or misleading statements regarding its business operations and prospects during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - Defendants are accused of overstating progress on prostate cancer therapeutic candidates [3]. - The quality and performance of the Company's supply chain and partners were allegedly exaggerated [3]. - As a result of these misrepresentations, statements regarding the Company's business and operations were claimed to be false or misleading [3]. Group 3: Company Background - Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, focusing on radiopharmaceutical development for cancer treatment [2].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. about a class action lawsuit due to alleged misleading statements regarding the company's progress and operations [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025 [3]. - Allegations include that Telix overstated its progress on prostate cancer therapeutic candidates and the quality of its supply chain and partners [3]. Shareholder Actions - Shareholders are encouraged to register for the class action by January 9, 2026, to potentially become lead plaintiffs [4]. - Registration allows shareholders to receive updates through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's prostate cancer therapeutic candidates and supply chain quality [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from February 21, 2025, to August 28, 2025 [1]. - The complaint claims that defendants overstated the progress of Telix's prostate cancer therapeutic candidates and the quality of its supply chain and partners [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of TLX during the specified timeframe are encouraged to register for the class action by January 9, 2026 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from February 21, 2025 to August 28, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of the Plaintiffs' Bar in 2020 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [8]. Group 2: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [5]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [6]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the FDA regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [7]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates, leading to significant investor losses [3][4][5]. Group 1: Allegations and Legal Actions - The complaint alleges that Telix and its executives materially overstated the progress of their prostate cancer therapeutic candidates and the quality of their supply chain, resulting in misleading statements about the company's business and prospects [3]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, which caused the price of Telix's American Depositary Shares to drop by over 13% in two trading sessions [4]. - Following the disclosure of a Complete Response Letter from the FDA on August 28, 2025, regarding deficiencies in the Chemistry, Manufacturing, and Controls package for TLX250-CDx, Telix's ADS price fell by more than 21% over two trading sessions [5]. Group 2: Class Action Details - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Telix is January 9, 2026, with the lead plaintiff being the investor with the largest financial interest who is typical of class members [6]. - Faruqi & Faruqi encourages anyone with information regarding Telix's conduct, including whistleblowers and former employees, to contact the firm [6].

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. due to alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding Telix's progress with prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects of the company [3]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role [4]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly misleading investors regarding the progress and quality of its prostate cancer therapeutic candidates and supply chain [1][2]. Allegations - The lawsuit claims that Telix Pharmaceuticals materially overstated the progress of its prostate cancer therapeutic candidates, TLX591 and TLX592, as well as the quality of its supply chain and partners [2]. - Investors were reportedly caught off guard when Telix disclosed an SEC investigation into its disclosures related to the development of its prostate cancer therapeutic candidates on July 22, 2025 [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA, citing deficiencies in chemistry, manufacturing, and controls, and requested additional data to establish comparability of the drug product used in the phase 3 clinical trial [3]. Impact on Stock - Following the announcement of the SEC investigation and the FDA's CRL, the price of Telix's American Depositary Shares (ADSs) declined significantly [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by January 9, 2026, but participation is not required to be eligible for recovery [4]. About Robbins LLP - Robbins LLP is a law firm specializing in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].